<DOC>
<DOCNO>EP-0620003</DOCNO> 
<TEXT>
<INVENTION-TITLE>
VASOPRESSIN ANTAGONIST AND OXYTOCIN ANTAGONIST
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D40300	C07D52100	C07D40500	C07D40306	A61K3155	A61K3155	C07D40500	C07D22316	A61K3160	C07D40106	C07D40100	C07D40512	C07D40112	C07D52100	A61K3160	C07D40100	C07D22300	C07D40312	C07D40300	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	C07D	C07D	C07D	A61K	A61K	C07D	C07D	A61K	C07D	C07D	C07D	C07D	C07D	A61K	C07D	C07D	C07D	C07D	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D403	C07D521	C07D405	C07D403	A61K31	A61K31	C07D405	C07D223	A61K31	C07D401	C07D401	C07D405	C07D401	C07D521	A61K31	C07D401	C07D223	C07D403	C07D403	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
A benzazepine compound represented by formulae (I) or (II) or a salt thereof, and a vasopressin antagonist or an oxytocin 
antagonist containing the above compound as the active ingredient. 


</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
The present invention relates to a vasopressin antagonist and oxytocin antagonist containing a benzoheterocyclic compound as an active ingredient.Some of benzoheterocyclic compounds being used as the active ingredients in the vasopressin antagonists and oxytocin antagonists which are represented by the general formula (1) containing novel compounds.Some benzoheterocyclic compounds having chemical structural formulae similar to those of benzoheterocyclic compounds according to the present invention are disclosed in EP-A-0382185 A2 (Publication Date: August 15, 1990); WO 91/05549 (Publication Date: May 2, 1991) and EP-A-0470514A1 (Publication Date: February 12, 1992). Furthermore, EP-A-0514667A1 (Publication Date: November 25, 1992) discloses benzoheterocyclic compounds, and is known as the junior patent application of the present invention.The substituents bonded at 1-position in the benzoheterocyclic compounds disclosed in these prior art references are substantially different from the substituents bonded at 1-position in the benzoheterocyclic compounds according to the present invention.Br.J Pharmacol (1992), 105, 787-791) discloses vasopressin antagonist OPC-31260 having a dimethylamino substituent in the 5-position of the benzoheterocyclic ring.The benzoheterocyclic compounds or a salts thereof of the present invention are prepresented by the general formula (1A) as follows:

wherein:
R1 is a halogen atom,R2 is a hydrogen atom, a C1-6 alkyl group, a hydroxyl group, a halogen atom or a C1-6 alkoxy group;R3 is a group of the formula:

(wherein R13 is a halogen atom, a hydroxyl group, a carbamoyl group, or a C1-6 alkyl group; m is 0 or an integer of 1 to 3),R4 is
(I) a group of the formula:

(wherein A is a C1-6 alkylene group; R11 is a hydrogen atom or a C1-6 alkyl group; and R12 is a hydroxyl group-substituted C1-6 alkyl group, a pyridyl-substituted C1-6 alkyl group, a pyridyl group,
a group of the formula:

(wherein A is the same as defined above; and R39 and R40 are the same or different, and are each a hydrogen atom, a C1-6 alkyl group which may have hydroxyl groups as the substituents;
further R39 and R40 may form a 5- or 6-membered saturated heterocyclic group, by combining with the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom, said heterocyclic ring may have C1-6 alkyl groups on the heterocyclic ring), or a pyrrolidinyl-substituted C1-6 alkyl group which may have, as the substituents, C1-6 alkyl groups on the pyrrolidine ring;
further,
</DESCRIPTION>
<CLAIMS>
A benzoheterocyclic compound or a salt thereof represented by the general formula (1A):


wherein:

R
1
 is a halogen atom,
R
2
 is a hydrogen atom, a C
1-6
 alkyl group, a hydroxyl group, a halogen atom or a C
1-6
 alkoxy group;
R
3
 is a group of the formula:


(wherein R
13
 is a halogen atom, a hydroxyl group, a carbamoyl group, or a C
1-6
 alkyl group; m is 0 or an integer of 1 to 3),
R
4
 is

(I) a group of the formula:


(wherein A is a C
1-6
 alkylene group; R
11
 is a hydrogen atom or a C
1-6
 alkyl group; and R
12
 is a hydroxyl group-substituted C
1-6
 alkyl group, a pyridyl-substituted C
1-6
 alkyl group, a pyridyl group, a group of the formula:


(wherein A is the same as defined above; and R
39
 and R
40
 are the same or different, and are each a hydrogen atom, a C
1-6
 alkyl group which may have hydroxyl groups as the substituents;

further R
39
 and R
40
 may form a 5- or 6-membered saturated heterocyclic group, by combining with the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom, said heterocyclic ring may have C
1-6
 alkyl groups on the heterocyclic ring), or a pyrrolidinyl-substituted C
1-6
 alkyl group which may have, as the substituents, C
1-6
 alkyl groups on the pyrrolidine ring;

further, R
11
 and R
12
 may form 5- to 7-membered saturated heterocyclic group, by combining with the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom; said heterocyclic group may be substituted with a C
1-6
 alkyl group, a C
1-6
 alkoxy-carbonyl group, an amino group which may have substituents selected
 from the group consisting of a C
1-6
 alkyl group and a C
1-6
 alkanoyl group, a C
1-6
 alkoxycarbonyl-substituted C
1-6
 alkyl group, a phenyl group which may have halogen atoms on the phenyl ring, a cyano-substituted C
1-6
 alkyl group, a C
2-6
 alkenyl group, an oxyranyl-substituted C
1-6
 alkyl group, a carbamoyl-substituted C
1-6
 alkyl group, or a C
1-6
 alkyl group having 1 to 2 substituents selected from the group consisting of a hydroxyl group and an amino group which may have C
1-6
 alkyl group,
(II) a group of the formula:


(wherein A is the same as defined above; R
23
 is a hydrogen atom or a C
1-6
 alkyl group; and R
24
 is a group of the formula:


(wherein B is a alkylene group; R
23A
 and R
24A
 are the same or different, and are each a hydrogen atom or a C
1-6
 alkyl group; further R
23A
 and R
24A
 may form a 5- to 6-membered saturated heterocyclic group, by combining with the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom),

further R
23
 and R
24
 may form a 7-membered saturated heterocyclic group, by combining with the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom, said heterocyclic group may have C
1-6
 alkyl groups as the substituents),
(III) a group of the formula:


(wherein A is the same as defined above; R
27
 is a hydrogen atom or a C
1-6
 alkyl group, R
28
 is a C
2-6
 alkenyl group, a C
2-6
 alkinyl group, or a C
1-6
 alkylsulfonyl group, or a cycloalkyl group;

further, R
27
 and R
28
 may form a 5- to 10-membered single ring or binary ring saturated or unsaturated heterocyclic group, by combining with the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom, said heterocyclic group is substituted with a C
1-6
 alkanoylamino group on the heterocyclic ring),
(IV) a group of the formula:


(wherein A is the same as defined above; R
29
 is a hydrogen atom or a C
1-6
 alkyl group; R
30
 is a C
2-6
 alkenyl group, a cycloalkyl group or a C
2-6
 alkinyl group; further R
29
 and R
30
 may form a 5- to 6-membered saturated heterocyclic group, by combining with the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom; said heterocyclic group is substituted with an amino group having a C
1-6
 alkanoyl group,
(V) a halogen atom-substituted C
1-6
 alkyl group, an imidazolyl-substituted C
1-6
 alkyl group, a 1,2,4-triazolyl-substituted C
1-6
 alkoxy group, a 1,2,3,4-tetrazolyl-substituted C
1-6
 alkoxy group, a 1,2,3,5-tetrazolyl-substituted C
1-6
 alkoxy group, a 1,2,3,4-tetrazolyl-substituted
 C
1-6
 alkyl group, a 1,2,3,5-tetrazolyl-substituted C
1-6
 alkyl group, 1,2,4-triazolyl-substituted C
1-6
 alkyl group, an imidazolthio-substituted C
1-6
 alkoxy group, a pyridylsulfinyl-substituted C
1-6
 alkoxy group, or an imidazolylsulfinyl-substituted C
1-6
 alkoxy group;
R
5
 is a hydrogen atom or a hydroxyl group;

provided that

when R
11
 and R
12
 form a saturated heterocyclic group, by combining together with the adjacent nitrogen atom with or without other nitrogen atom or oxygen atom, and said heterocyclic group may have, as the substituents, selected from the group consisting of a C
1-6
 alkyl group, a C
1-6
 alkoxycarbonyl group and an amino group which may have, as the substituents, selected from the group consisting of a C
1-6
 alkyl group and a C
1-6
 alkanoyl group,

then said saturated heterocyclic group being formed by combining with R
11
 and R
12
 should be a 7-membered heterocylic group.
The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
4
 is

a halogen atom-substituted C
1-6
 alkyl group,
an imidazolyl-substituted C
1-6
 alkyl group,
a 1,2,4-triazolyl-substituted C
1-6
 alkoxy group,
a 1,2,3,4-tetrazolyl-substitued C
1-6
 alkoxy group,
a 1,2,3,5-tetrazolyl-substitued C
1-6
 alkoxy group,
a 1,2,3,4-tetrazolyl-substitued C
1-6
 alkyl group,
a 1,2,3,5-tetrazolyl-substitued C
1-6
 alkyl group,
a 1,2,4-triazolyl-substituted C
1-6
 alkyl group,
an imidazolthio-substituted C
1-6
 alkoxy group,
a pyridylsulfinyl-substituted C
1-6
 alkoxy group, or
an imidazolylsulfinyl-substituted C
1-6
 alkoxy group.
The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
4
 is a group of the formula:

The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
4
 is a group of the formula:

The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
4
 is a group of the formula:

The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
4
 is a group of the formula:

The benzoheterocyclic compound or a salt thereof according to any one of claims 1 to 6, wherein R
2
 is a C
1-6
 alkyl group or a C
1-6
 alkoxy group, R
3
 is a group of the formula:


(wherein R
13
 is a halogen atom or a C
1-6
 alkyl group), and R
5
 is a hydrogen atom.
The benzoheterocyclic compound or a salt thereof according to any one of claims 1 to 6, wherein R
2
 is a hydrogen atom, a hydroxyl group or a halogen atom; R
3
 is a group of the formula:


(wherein R
13
 is a halogen atom or a C
1-6
 alkyl group), and R
5
 is a hydrogen atom.
The benzoheterocyclic compound or a salt thereof according to any one of claims 1 to 6, wherein R
2
 is a C
1-6
 alkyl group or a C
1-6
 alkoxy group; R
3
 is a group of the formula:


(wherein R
13
 is a hydroxyl group, or a carbamoyl group), and R
5
 is a hydrogen atom.
The benzoheterocyclic compound or a salt thereof according to any one of claim 1 to 6, wherein R
2
 is a hydrogen atom, a hydroxyl group or a halogen atom;

R
3
 is a group of the formula:


(wherein R
13
 is a hydroxyl group, or a carbamoyl group), and R
5
 is a hydrogen atom.
The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
5
 is a hydroxyl group.
The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
11
 is a hydrogen atom or a C
1-6
 alkyl group; R
12
 is a hydroxy-substituted C
1-6
 alkyl group, a pyridyl-substituted C
1-6
 alkyl group, a pyridyl group, or a pyrrolidinyl-substituted C
1-6
 alkyl group which may have, as the substituents, C
1-6
 alkyl groups on the pyrrolidine ring, or a salt thereof.
The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
11
 is a hydrogen atom, or a C
1-6
 alkyl group; R
12
 is a group of the formula:


(wherein R
39
 and R
40
 are the same or different, and are each a hydrogen atom or a C
1-6
 alkyl group which may have hydroxyl groups as the substituents; R
39
 and R
40
 may form a 5- to 6-membered saturated heterocyclic group, by combining with the adjacent nitrogen atom, together with or without other nitrogen atom or oxygen atom, said heterocyclic group may be substituted with C
1-6
 alkyl groups thereon).
The benzoheterocyclic compound or a salt thereof according to claim 1, wherein R
11
 and R
12
 may form a 5- to 7-membered saturated heterocyclic group, by combining with the adjacent nitrogen atom being bonded thereto, together with or without other nitrogen atom or oxygen atom; said heterocyclic group may be substituted with a C
1-6
 alkyl group, a C
1-6
 alkoxycarbonyl group, an amino group which may have the substituents selected from the group consisting of a C
1-6
 alkyl group and a C
1-6
 alkanoyl group, a C
1-6
 alkoxycarbonyl-substituted C
1-6
 alkyl group, a phenyl group which may have halogen atoms on the phenyl ring, a cyano-substituted C
1-6
 alkyl group, a C
2-6
 alkenyl group, an oxyranyl-substituted alkyl group, a carbamoyl-substituted C
1-6
 alkyl group, or a C
1-6
 alkyl group having 1 to 2 substituents selected from the group consisting of a hydroxyl group and an amino group which may have C
1-6
 alkyl group.
The benzoheterocyclic compound or a salt thereof according to claim 1, which is

7-Chloro-5-[N-(2-dimethylaminoethyl)-N-methyl-amino]-carbonylmethyl-1-[3-methoxy-4-(2-bromo-benzoylamino)benzoyl]
-2,3,4,5-tetrahydro-1H-benzoazepine.
A vasopressin antagonistic composition which comprises, as an active ingredient, a benzoheterocyclic compound represented by the general formula. (1A) according to claim 1, or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or diluent.
A pharmaceutical composition comprising, as an active ingredient, a benzoheterocyclic compound or a salt thereof according to any one of claims 1 to 15, in admixture with a pharmaceutically acceptable carrier or diluent.
Use of a benzoheterocyclic compound or a salt thereof according to any one of claims 1 to 15, as an active ingredient for the preparation of a pharmaceutical composition for the use as a vasopressin antagonist.
Use of a benzoheterocyclic compound or a salt thereof according to any one of claims 1 to 15, as an active ingredient for the preparation of a pharmaceutical composition for the use as an oxytocin antagonist.
</CLAIMS>
</TEXT>
</DOC>
